EP0721339A1 - ENZYME $(g)-GALACTOSIDASE RECOMBINANTE ET ADN c? CODANT CETTE ENZYME - Google Patents

ENZYME $(g)-GALACTOSIDASE RECOMBINANTE ET ADN c? CODANT CETTE ENZYME

Info

Publication number
EP0721339A1
EP0721339A1 EP94926604A EP94926604A EP0721339A1 EP 0721339 A1 EP0721339 A1 EP 0721339A1 EP 94926604 A EP94926604 A EP 94926604A EP 94926604 A EP94926604 A EP 94926604A EP 0721339 A1 EP0721339 A1 EP 0721339A1
Authority
EP
European Patent Office
Prior art keywords
coffee bean
galactosidase
leu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94926604A
Other languages
German (de)
English (en)
Other versions
EP0721339A4 (fr
Inventor
Alex Zhu
Jack Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of EP0721339A1 publication Critical patent/EP0721339A1/fr
Publication of EP0721339A4 publication Critical patent/EP0721339A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a recombinant enzyme for use in the removal of type B antigens from the surface of cells in blood products, thereby converting type B blood products to type 0 blood products and type AB blood products to type A blood products without otherwise affecting the structure and function of the cells in the blood products.
  • This invention further relates to methods of cloning and expressing said recombinant enzyme.
  • this invention is directed to a recombinant coffee bean ⁇ -galactosidase enzyme, a recombinant vector which encodes coffee bean ⁇ -galactosidase, methods of cloning and expressing said recombinant ⁇ -galactosidase enzyme, the use of said recombinant ⁇ -galactosidase enzyme to cleave galactose sugar residues, most particularly ⁇ l,3-lin ed galactose residues, which are responsible for blood group B specificity, and a method of removing type B antigens from the surface of cells in type B and AB blood products using said recombinant coffee bean ⁇ -galactosidase enzyme by contacting said enzyme with blood products so as to remove the terminal moiety of the B-antigenic determinant from the surface of cells (for example, erythrocytes) in said blood products.
  • the recombinant coffee bean ⁇ -galactosidase enzyme of this invention provides a readily available and cost-efficient enzyme which can be used in the removal of type B antigens from the surface of cells in type B and AB blood products.
  • Treatment of type B blood products with the recombinant enzyme of this invention provides a source of cells free of the B antigen, which blood products are thereby rendered useful in transfusion therapy in the same manner as 0 type blood products.
  • blood products includes whole blood and cellular components derived from blood, including erythrocytes (red blood cells) and platelets.
  • This system is based on the presence or absence of antigens A and/or B. These antigens are found on the surface of erythrocytes and on the surface of all endothelial and most epithelial cells as well.
  • the major blood product used for transfusion is erythrocytes, which are red blood cells containing hemoglobin, the principal function of which is the
  • Blood of group A contains antigen A on its erythrocytes.
  • blood of group B contains antigen B on its erythrocytes.
  • Blood of group AB contains both antigens, and blood of group O contains neither antigen, but does contain a structure known as H antigen.
  • the blood group structures are glycoproteins or glycolipids and considerable work has been done to identify the specific structures making up the A and B determinants or antigens. It has been found that the blood group specificity is determined by the nature and linkage of monosaccharides at the ends of the carbohydrate chains.
  • the carbohydrate chains are attached to a peptide or lipid backbone which is embedded in the lipid bi-layer of the membrane of the cells.
  • the most important (immuno-dominant or immuno-determinant) sugar has been found to be N-acetylgalactosamine for the type A antigen and galactose for the type B antigen.
  • Blood of group A contains antibodies to antigen B. Conversely, blood of group B contains antibodies to antigen A. Blood of group AB has neither antibody, and blood group 0 has both. A person whose blood contains either (or both) of the anti-A or anti-B antibodies cannot receive a transfusion of blood containing the corresponding incompatible antigen(s). If a person receives a transfusion of blood of an incompatible group, the blood transfusion recipient's antibodies coat the red blood cells of the transfused incompatible group and cause
  • transfused red blood cells to agglutinate, or stick together.
  • Transfusion reactions and/or hemolysis the destruction of red blood cells
  • transfusion blood type is cross-matched against the blood type of the transfusion recipient.
  • a blood type A recipient can be safely transfused with type A blood which contains compatible antigens.
  • type O blood contains no A or B antigens, it can be transfused into any recipient with any blood type, i.e., recipients with blood types A, B, AB or O.
  • type O blood is considered "universal", and may be used for all transfusions.
  • the process for converting B and AB erythrocytes which is described in the '619 Patent includes the steps of equilibrating B or AB erythrocytes, contacting the equilibrated erythrocytes and purified ⁇ -galactosidase for a period of time sufficient to convert the B antigen in the erythrocytes to the H antigen, removing the ⁇ -galactosidase enzyme from the erythrocytes and re-equilibrating the erythrocytes.
  • these synthetic substrates and other oligosaccharide substrates are structurally simple and small-sized, and mimic only a portion of the natural glycoproteins and glycolipid structures (glycoconjugates) which are of primary concern, those being the B antigens on the surface of cells.
  • ⁇ -galactosidase enzymes from a number of sources have been purified, sequenced, cloned and expressed. (See, for example, Fellinger et al. , Yeast, Vol. 7, pp. 463-473 (1991) (expression of guar ⁇ -galactosidase); Yagi et al. , Archives Biochem. and Biophysics, Vol. 280, pp.
  • substrate specificity is measured in the Km value, which measures the binding constant or affinity of an enzyme for a particular substrate. The lower
  • Vmax Km the reaction rate at a saturating concentration of substrate.
  • Vmax Km the reaction rate at a saturating concentration of substrate.
  • Vmax Km the reaction rate at a saturating concentration of substrate.
  • a higher Vmax indicates a faster cleavage rate.
  • Vmax Km is a measure of the overall efficiency of an enzyme in reacting with (cleaving) a given substrate.
  • a higher Vmax/Km indicates greater enzyme efficiency.
  • the enzyme For successful and clinically applicable removal of B antigens from the surface of cells, the enzyme must be sufficiently active at or above a pH at which the cells being treated that can be maintained, that being pH 5.6 (or above) for red cells. Therefore, the pH optimum and activity profile of an appropriate enzyme must still provide reasonable enzyme activity at this pH.
  • the pH optimum of Ehrlich cell ⁇ -galactosidase enzyme centers near 4.5, irrespective of substrate (see Yagi et al.. Archives Biochem. and Biophysics, Vol. 280, pp. 61-67 (1990)).
  • the pH optimum or Ehrlich cell ⁇ -galactosidase has been found to be 4.5 for water-soluble fluorogenic substrates and oligosaccharides (see Dean et al., J. Biol ⁇ Chem. , Vol. 254, pp. 10006-10010 (1979)).
  • the pH optimum of coffee bean ⁇ -galactosidase for the fluorogenic substrate PNP- ⁇ -Gal is 6.0, indicating that the coffee bean enzyme exhibits significant activity at or above a pH at which cells are treated for removal of B antigens.
  • Coffee bean ⁇ -galactosidase enzyme shows a Vmax/km value of 236 at pH 6.0 toward PNP- ⁇ -gal
  • ⁇ -galactosidases isolated from human cells see Dean and Sweeley, J. Biol. Chem. , Vol. 254, pp. 10006-10010 (1979)
  • Ehrlich ascites tumor see Yagi et al.. Archives Biochem. and Biophysics, Vol. 280, pp. 61-67 (1990)
  • Vmax/Km value of between 7.59 and 9.9 at pH 4.5-4.6 (using 4-Me- ⁇ -gal or PNP- ⁇ -gal).
  • coffee bean ⁇ -galactosidase can be used to convert B and AB blood products, a need has arisen to develop a coffee bean ⁇ -galactosidase enzyme source which is more readily available.
  • a need has arisen to develop a coffee bean ⁇ -galactosidase enzyme useful in type B and AB blood product conversion, the production of which enzyme is cost-efficient.
  • a recombinant, cloned enzyme would allow for specific protein sequence modifications, which can be introduced in order to generate an enzyme with further optimized specific activity, substrate specificity and pH range.
  • This invention is directed to a recombinant coffee bean ⁇ -galactosidase enzyme capable of cleaving ⁇ l,3-linked glyco ⁇ ide linkages on cells.
  • This invention is further directed to a recombinant vector containing a nucleotide sequence encoding coffee bean ⁇ -galactosidase. Additionally, this invention is directed to a method of producing coffee bean
  • ⁇ -galactosidase ⁇ -galactosidase
  • a method of removing B antigens from the surface of cells which method comprises contacting cells with recombinant coffee bean ⁇ -galacto ⁇ idase enzyme for a period of time sufficient to remove the B antigens from the surface of the cells.
  • Figure 1 represents the nucleotide and deduced amino acid sequence of full-length cDNA encoding coffee bean ⁇ -galactosidase
  • Figure 2 represents a comparison of sequence homology of ⁇ -galactosidase from coffee bean, guar (Cyamopsis tetraqonoloba) , human placenta, yeast (Saccharomyces eerevisiae) and fungi (Aspergillus niger) as aligned using the computer program PROSIS and manual arrangement;
  • Figure 3 represents immunoprecipitation with polyclonal antibody of cloned coffee bean ⁇ -galactosidase expressed in vitro in rabbit reticulocyte lysate and wheat germ extract, as analyzed by SDS-PAGE and autoradiographed;
  • Figure 4 represents Western blot analysis of recombinant coffee bean ⁇ -galacto ⁇ idase expressed in transfected sf9 insect cells using antibody against purified coffee bean ⁇ -galactosidase.
  • This invention is directed to a recombinant coffee bean ⁇ -galactosidase enzyme capable of cleaving ⁇ l,3-1inked glycoside linkages on cells.
  • the recombinant coffee bean ⁇ -galactosidase enzyme of the invention has a molecular weight of about 42 kDa, and has about 80% amino acid sequence homology with guar ⁇ -galactosidase enzyme.
  • This invention is further directed to a recombinant vector containing a nucleotide sequence which encodes coffee bean ⁇ -galactosidase.
  • this invention is directed to a method of producing coffee bean ⁇ -galactosidase, and to a method of removing B antigens from the surface of cells which method comprises contacting cells with a recombinant coffee bean ⁇ -galactosidase enzyme for a period of time sufficient to remove the B antigens from the surface of the cells.
  • Group B erythrocytes may be treated with ⁇ -galactosidase isolated from coffee beans to cleave the terminal ⁇ l,3-linked galactose residues responsible for blood group B specificity in order to convert the group B erythrocytes serologically to group O erythrocytes.
  • ⁇ -galacto ⁇ idase has been purified from several sources. However, only coffee bean ⁇ -galactosidase cleaves ⁇ l,3-linked galactose residues responsible for blood group B specificity. Hence, only coffee bean ⁇ -galactosidase can be used to convert type B blood products to type 0 blood products, and type AB blood products to type A blood products.
  • the full length cDNA which encodes coffee bean ⁇ -galactosidase is as follows: SEQ ID NO: 1
  • ATC AAT CTT GAT GAC TGT TGG GCA GAA CTT AAC AGA GAT TCA CAG GGG 335 lie Asn Leu Asp Asp Cys Trp Ala Glu Leu Asn Arg Asp Ser Gin Gly
  • a DNA vector containing a sequence encoding coffee bean ⁇ -galactosidase was deposited under the Budapest Treaty with the American Type Culture Collection, Rockville, Maryland, on September 8, 1993, tested and found viable on ,
  • expression vectors containing the coffee bean ⁇ -galactosidase coding sequence can be used to construct expression vectors containing the coffee bean ⁇ -galactosidase coding sequence, with appropriate transcriptional/translational signals for expression of the enzyme in the corresponding expression systems.
  • Appropriate organisms, cell types and expression systems include: cell-free systems such as a rabbit reticulocyte lysate system, prokaryotic bacteria, such as E. coli, eukaryotic cells, such as yeast, insect cells, mammalian cells (including human hepatocytes or Chinese hamster ovary (CHO) cells), plant cells or systems, and animal systems including oocytes and transgenic animals.
  • a recombinant coffee bean ⁇ -galactosidase enzyme is cloned and expressed, said enzyme can be used to remove B antigens from the surface of cells in blood products.
  • Type B antigens can be removed from the surface of erythrocytes by contacting the erythrocytes with the recombinant coffee bean ⁇ -galactosidase enzyme of the invention for a period of time sufficient to remove the B antigens from the surface of the erythrocytes.
  • coffee bean ⁇ -galactosidase was purified to apparent homogeneity from green coffee beans.
  • the procedure used for purification of ⁇ -galactosidase from coffee beans was developed and optimized in the laboratory to provide pure ⁇ -galactosidase enzyme (demonstrating a single band on SDS polyacrylamide gel electrophoresis) with optimal yields under large scale conditions. This provided sufficient material to be used for treatment of type B blood products to remove B antigens on a clinical scale.
  • Green Santos beans were frozen in either liquid nitrogen or in a -70°C freezer to facilitate grinding in a Waring blender.
  • the crude powder obtained was homogenized with H 2 0 (at a ratio of .4 liters H 2 0 per kg ground beans) and
  • PCS buffer pH 5.6 had the following composition: 58 mM dibasic sodium phosphate, 21 mM citric acid, 77 mM sodium chloride.
  • Concentrate phosphate-citrate buffer was prepared by titrating 50 mM citric acid with 100 mM dibasic sodium phosphate pH 3.7.
  • Sepharose divinylsulfone galactose was prepared according to the procedure described by Ersson et al. , Biochem. et Biophys. Acta, Vol. 494, pp.
  • PBE94 Polybuffer exchanger 4
  • Other similar anion exchange resins which are well known in the art and available commercially, can be used in place of DE53 in the above procedure, particularly other DEAE (diethylaminoethyl) resins.
  • Microsequencing of the unblocked mature enzyme provided an amino-terminal sequence (N-pep) of 19 residues.
  • N-pep amino-terminal sequence
  • 0.2 mg of the purified ⁇ -galactosidase was treated with 2 mg of cyanogen bromide in 70% formic acid for 24 hours at room temperature in the dark.
  • the peptides were isolated by reverse phase HPLC.
  • Two peptide sequences, 2-pep and 3- ⁇ ep, were then determined by automated gas phase microsequencing.
  • the sequences of the three peptides are indicated in Figure 1.
  • Figure 1 represents the full length cDNA encoding coffee bean ⁇ -galactosidase.
  • the first 15 amino acids comprise a putative signal peptide which is cleaved during biosynthesis. Therefore, the mature coffee bean ⁇ -galactosidase enzyme is comprised of the amino acids 16-378 of Figure 1.
  • the potential N-linked glycosylation site is double-underlined at amino acid residues 160-162.
  • the polyadenylation signal (AATAAA) at the position ntl361-1366 is boxed.
  • the oligonucleotides, CB1, CB4 through CB9, are shown with arrows to indicate 5' to 3' direction.
  • the CBl* was designed as 5'ACA(CT)CCA(T)CCA(T)ATGGNTGGAA.
  • the CB4* based on the sequence of the peptide, 3-pep, has the sequence 5'-TGT(A)GGT(GA)GTNAGG(CA)ACG(A)TACAT.
  • CBl bears the least codon degeneracies in the peptide sequence of N-pep as determined by the computer program "Primer” (Scientific and Educational Software, Inc.).
  • RNA was prepared from 2 grams of dried green coffee beans by using the Extract-A-plant RNA Isolation kit (ClonTech) according to the manufacturer's procedure. The quality of the isolated RNA was confirmed by denaturing agarose gel electrophoresis. The messenger RNA was purified from the total RNA by using an oligo-dT column (ClonTech) . In order to isolate the specific cDNA encoding the ⁇ -galactosidase, cDNA using isolated coffee bean mRNA was prepared according to the standard procedure known in the art for reverse transcription.
  • oligo dT A mixture of oligo dT and random primer was used as the reverse transcription primer in the reaction to avoid the 3' bias when oligo-dT is used alone.
  • the cDNA then provided the template in a PCR reaction for 35 cycles, 94 ⁇ C 1 minute, 50 ⁇ C 2 minutes and 72 ⁇ C 3 minutes.
  • this PCR procedure produced a fragment of approximately l.lkb. This fragment, designated BZ, was cloned directly into the pCRII vector (Invitrogen) for further analysis.
  • BZ corresponds to sequence nucleotides (nt) 168 to 1234 in Figure 1). Furthermore, its deduced amino acid sequence matched the peptide sequences obtained from purified coffee bean ⁇ -galactosidase, providing evidence for its authenticity as coffee bean ⁇ -galactosidase cDNA.
  • the second oligonucleotide, CB6, together with the universal primer was used to amplify the 5' region upstream of the coding sequence by PCR. Since no distinctive DNA band was visible on the agarose gel after two PCR amplifications, the PCR product mixture was cloned into the pCRII vector and screened by hybridizing the colonies with the radioactively labeled l.lkb fragment BZ (sequence ntl68-1234 in Figure 1). The positive colonies were picked for plasmid preparation.
  • the sequencing of the plasmid indicated that the DNA fragment, designated 5'BZ, obtained by the 5' RACE technique contained a 240bp overlap (the sequence between CBl and CB6) with the BZ, and about a 170bp further upstream sequence which includes the N-terminus of the mature enzyme and the putative signal peptide sequence.
  • the cDNA was reverse-transcribed from coffee bean mRNA by using a primer, PI, which has the sequence 5'-GACTCGAGTCGACATCGA-(T) 17 .
  • PCR amplification was then carried out with a specific primer CB7 (sequence nt940-957 in Figure 1) and an adapter primer, PII.
  • PH has the same sequence as PI except that it lacks seventeen thymidine residues at its 3' end.
  • the PCR product was analyzed on 1% low melting point agarose gel and a distinctive band of about 500 b long was visualized.
  • the fragment designated 3" BZ was
  • Oligonucleotide CB9 was made, which corresponded to sequence nt77-94 shown in Figure 1.
  • cDNA was synthesized from coffee bean mRNA using the 3' RACE technique as previously described.
  • a 1.35kb fragment was amplified by PCR using two primers CB9 and PII, and was then
  • the plasmids thus generated contained the 1.35kb insert in both orientations.
  • the plasmid pCR-BZ6 has the insert downstream of an SP6 promoter, which was used in in vitro expression.
  • a second plasmid pCR-BZ7 containing the opposite insert orientation was used for 0 subcloning the ⁇ -galactosidase cDNA into a baculovirus expression vector.
  • the sequence of the 1.35kb product matched with the corresponding sequences from the three separate fragments, 5'BZ, BZ and 3'BZ, confirming the authentic sequence of the coffee bean ⁇ -galactosidase cDNA shown in Figure 1. 5
  • the coffee bean ⁇ -galactosidase cDNA clone was characterized.
  • the sequence shown in the Figure 1 encodes a protein having a molecular weight of 42kDa, which closely approximates the size of the purified coffee bean ⁇ -galactosidase as estimated on SDS-PAGE, Three peptide sequences, N-pep, 2-pep and 3-pep, which were derived from purified enzyme, are underlined in Figure 1. These sequences matched the deduced amino acid sequences. This confirms that the cDNA clone isolated from coffee bean RNA encodes ⁇ -galactosidase.
  • the first plant ⁇ -galactosidase cDNA was cloned from guar (see Overbeeke et al. , Plant Molecular Biology, Vol. 13, pp. 541-550 (1989)). Guar ⁇ -galactosidase encodes a protein
  • Figure 2 represents the sequence homology of ⁇ -galactosidase from different sources.
  • the amino acid sequences of ⁇ -galactosidase from coffee bean (coffee), Cya opsis tetragonoloba (guar), human placenta (human), Saccharomyces eerevisiae (yeast) and Aspergillus niger (Aspergillus) were aligned by using the computer program PROSIS (Hitachi Software Engineering Corp., Ltd.) and manual arrangement. The gaps are created in order to show maximum similarity.
  • the numbers above the sequences indicate the relative position of each amino acid sequence.
  • yeast and Aspergillus niger ⁇ -galactosidases are truncated at the C-terminus, (indicated by *), removing 38 and 103 residues respectively. Identical or conservatively substituted amino acid residues (five out of six or more at the same position) are boxed according to the equivalent amino acid list.
  • 1 A,S,T,P and G; 2: N,D,E and Q; 3: H,R and K; 4: M,L,I and V; and 5: F,Y and W.
  • PROSIS Protein analysis program
  • plasmids Two plasmids were used: pCR-BZ6, which contains ⁇ -galactosidase cDNA downstream from the SP6 promoter, and the vector pCRII as a control.
  • the protein(s) were expressed in both rabbit reticulocyte lysate and wheat germ extract and then immunoprecipitated by the polyclonal antibody raised against purified coffee bean ⁇ -galactosidase. All the samples were analyzed by a SDS-PAGE and autoradiographed as shown in Figure 3.
  • Figure 3 represents in vitro expression and immunoprecipitation of cloned coffee bean ⁇ -galactosidase.
  • plasmids Approximately 2 ⁇ g of plasmids (pCR and pCR-BZ6) were added to 50 ⁇ l mixture of TNT rabbit reticulocyte lysate in the presence of 35S-methionine and SP6
  • the apparent discrepancy of the translation patterns in these two extracts may possibly be due to the fact that since the ⁇ -galacto ⁇ idase cDNA was isolated from coffee bean, its expression may be more optimized in the wheat germ extract.
  • the multiple bands observed in the rabbit reticulocyte lysate might result from alternative initiation or premature termination.
  • the results show that the 42 kDa protein expressed in vitro is coffee bean ⁇ -galactosidase.
  • Coffee bean ⁇ -galactosidase was then functionally expressed in insect cells. Many eukaryotic proteins have been expressed in insect cells infected with recombinant baculovirus
  • Coffee bean ⁇ -galactosidase cDNA was subcloned from the plasmid pCR-BZ7 into the unique Notl/BamHI sites of a baculovirus expression vector pVL 1392 (PharMingen), generating the plasmid pVL-BZ. Expression of ⁇ -galactosidase cDNA was thus under the control of a strong viral promoter (polyhedrin promoter) .
  • the plasmid pVL-BZ was co-transfected into sf9 insect cells with baculoGold DNA (PharMingen) , a lethal deletion of the virus DNA, according to the procedure suggested by the manufacturer.
  • viable virus containing the ⁇ -galactosidase cDNA was thus reconstituted inside the insect cells and released into the medium.
  • the transfection supernatant (1 ml) was then added to fresh sf9 cells (2 x 10 ). After incubation at 27°C for three days, the supernatant was harvested and used for virus amplification one more time in order to obtain a high titer of virus.
  • FIG. 4 represents expression of recombinant coffee bean ⁇ -galactosidase in insect cells (sf9). The supernatants and cells were collected after the second amplification and
  • the coffee bean ⁇ -galactosidase was expressed in the sf9 cells transfected with the plasmid pVL-BZ (lane 2) but not in cells transfected with wild-type virus (lane 4). Its migration on the gel was similar to that of purified enzyme (lane 5). In addition, secretion of the expressed protein in the culture supernatant (lane 1) was not detected.
  • the ⁇ -galactosidase activity was tested by directly incubating pVL-BZ transfected sf9 cells with 1.25 mM PNP- ⁇ -gal (pH 6.5). During the incubation, the PNP- ⁇ - galactosidase substrate enters the cells by diffusion.
  • the recombinant coffee bean ⁇ -galactosidase enzyme of the invention can be used to remove terminal galactose residues from the non-reducing end of carbohydrate chains (from polysaccharides and glycoconjugates), particularly those galactose residues which are ⁇ l,3-linked.
  • the recombinant coffee bean ⁇ -galactosidase enzyme of the invention can be used to convert type B erythrocytes to type 0 and type AB erythrocytes to type A. Specifically, the recombinant coffee bean ⁇ -galactosidase enzyme of the invention is put into contact with cells having B antigenicity for a period of time sufficient to remove the B antigens from the surface of the cells.
  • erythrocytes having B antigenicity are washed and then equilibrated in isotonic phosphate-citrate-sodium chloride (PCS) at pH 5.5 and 5.6, sequentially, ⁇ -galactosidase is added at a concentration of from 75 to 200 U/ml, and the mixture is incubated at 26°C. More preferably, the ⁇ -galactosidase is added at a concentration of 200 U/ml and the mixture is incubated at 26°C for 2.25 hours. Most preferably, the final hematocrit of the erythrocytes is 65 to 75%.
  • cells transformed with a recombinant vector which encodes coffee bean ⁇ -galactosidase can be cultured and coffee bean
  • ⁇ -galactosidase can be recovered from the culture, which coffee bean ⁇ -galactosidase can then be used to remove B antigens from the surface of cells and blood products.
  • ORGANISM Cyamopsis tetragonoloba
  • ORGANISM Saccharomyces eerevisiae
  • ORGANISM Aspergillus niger

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dairy Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une enzyme recombinante s'utilisant dans le but de supprimer des antigènes B de la surface de cellules de produits sanguins. Plus particulièrement, l'invention concerne une enzyme α-galactosidase recombinante de fève de café, un vecteur recombinant codant cette α-galactosidase de fève de café, des procédés de clonage et d'expression de α-galactosidase recombinante de fève de café, ainsi qu'un procédé de suppression d'antigènes B de la surface de cellules de produits sanguins au moyen de β-galactosidase recombinante de fève de café.
EP94926604A 1993-09-08 1994-08-26 ENZYME -(g)-GALACTOSIDASE RECOMBINANTE ET ADN c? CODANT CETTE ENZYME Withdrawn EP0721339A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11847093A 1993-09-08 1993-09-08
US118470 1993-09-08
PCT/US1994/009662 WO1995007088A1 (fr) 1993-09-08 1994-08-26 ENZYME $(g)-GALACTOSIDASE RECOMBINANTE ET ADNc CODANT CETTE ENZYME

Publications (2)

Publication Number Publication Date
EP0721339A1 true EP0721339A1 (fr) 1996-07-17
EP0721339A4 EP0721339A4 (fr) 1997-05-21

Family

ID=22378805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94926604A Withdrawn EP0721339A4 (fr) 1993-09-08 1994-08-26 ENZYME -(g)-GALACTOSIDASE RECOMBINANTE ET ADN c? CODANT CETTE ENZYME

Country Status (6)

Country Link
EP (1) EP0721339A4 (fr)
JP (1) JPH09502349A (fr)
AU (1) AU703180B2 (fr)
IL (1) IL110892A (fr)
WO (1) WO1995007088A1 (fr)
ZA (1) ZA946796B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606042A (en) * 1994-09-08 1997-02-25 The Curators Of The University Of Missouri Glycine α-D-galactosidases
GB9524752D0 (en) * 1995-12-04 1996-02-07 Danisco Modification process
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6630339B1 (en) * 2000-08-04 2003-10-07 The Curators Of The University Of Missouri Glycine and phaseolus α-D-galactosidases
CN114875084B (zh) * 2021-02-05 2023-10-20 上海交通大学 一种利用酶级联反应合成(1r,2r)-ampp的方法
CN114752581B (zh) * 2022-04-20 2023-05-26 南京工业大学 一种α-半乳糖苷酶突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046176A2 (fr) * 1980-08-14 1982-02-24 New York Blood Center, Inc. Conversion enzymatique de cellules rouges pour transfusions
WO1987007641A1 (fr) * 1986-06-03 1987-12-17 Unilever Nv Production de alpha-galactosidase de guar par des hotes transformes par des procedes d'adn recombinant
WO1995006478A1 (fr) * 1993-08-30 1995-03-09 Hawaii Biotechnology Group, Inc. α-GALACTOSIDASE RECOMBINANTE DE FEVE DE CAFE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0046176A2 (fr) * 1980-08-14 1982-02-24 New York Blood Center, Inc. Conversion enzymatique de cellules rouges pour transfusions
WO1987007641A1 (fr) * 1986-06-03 1987-12-17 Unilever Nv Production de alpha-galactosidase de guar par des hotes transformes par des procedes d'adn recombinant
WO1995006478A1 (fr) * 1993-08-30 1995-03-09 Hawaii Biotechnology Group, Inc. α-GALACTOSIDASE RECOMBINANTE DE FEVE DE CAFE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEM BIOPHYS RES COMMUN, DEC 31 1991, 181 (3) P1564-71, UNITED STATES, XP002024533 DESNICK, ROBERT J. BISHOP, DAVID F. IOANNOU, YIANNIS A.: "Purification and characterization of a Coffea canephora alpha-D-galactosidase isozyme." *
HARPAZ N. ET AL: 'Purification of coffee bean alpha-galactosidase by affinity chromatography' BIOCHIMICA ET BIOPHYSICA ACTA vol. 341, 1974, pages 213 - 221 *
METHODS ENZYMOL. (1988), 160(BIOMASS, PT. A), 627-32 CODEN: MENZAU;ISSN: 0076-6879, XP000616694 MCCLEARY, BARRY V.: ".alpha.-D-Galactosidase from lucerne and guar seed" *
See also references of WO9507088A1 *

Also Published As

Publication number Publication date
IL110892A (en) 1999-12-22
AU703180B2 (en) 1999-03-18
WO1995007088A1 (fr) 1995-03-16
JPH09502349A (ja) 1997-03-11
IL110892A0 (en) 1994-11-28
ZA946796B (en) 1995-05-10
AU7639294A (en) 1995-03-27
EP0721339A4 (fr) 1997-05-21

Similar Documents

Publication Publication Date Title
ES2168101T5 (es) Clonacion y expresion de alfa-galactosidasa a biologicamente activa.
Møller et al. Intra-and extracellular β-galactosidases from Bifidobacterium bifidum and B. infantis: molecular cloning, heterologous expression, and comparative characterization
JPH09501044A (ja) ＵＤＰ−ＧＡＬＮＡｃ：ポリペプチド、Ｎ−アセチルガラクトサミニルトランスフェラーゼをコードするクローン化されたＤＮＡ
PL190041B1 (pl) Zastosowanie ludzkiej komórki, cząsteczka DNA, konstrukt ekspresji, hodowana ludzka komórka, klonujący szczep komórek, klonująca linia komórek, białko, sposób wytwarzania glikozylowanej ludzkiej alfa-galaktozydazy A, oczyszczona glikozylowana ludzkaalfa-galaktozydaza A, sposób oczyszczania ludzkiej alfa-galaktozydazy A, zastosowanie oczyszczonej glikozylowanej ludzkiej alfa-galaktozydazy A, kompozycja terapeutyczna i sposób oczyszczania ludzkiej alfa-galaktozydazy A z próbki
EP2502491B1 (fr) Nouvelles a-galactosidases
EP0739983A2 (fr) Gène codant pour lacto-N-biosidase
AU4772596A (en) Recombinant alpha-galactosidase enzyme
AU703180B2 (en) Recombinant alpha-galactosidase enzyme and cDNA encoding said enzyme
Merkle et al. Cloning, expression, purification, and characterization of the murine lysosomal acid α-mannosidase
JPH10313867A (ja) グルクロン酸転移酵素をコードするｄｎａ
US6228631B1 (en) Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
US5610063A (en) cDNA for α-N-acetyl-galactosaminidase from Gallus domesticus
Zhu et al. Cloning and characterization of a cDNA encoding chicken liver α-N-acetylgalactosaminidase
WO1998011246A2 (fr) ENDO-β-GALACTOSIDASE
EP0585083B1 (fr) Gène de glycosyltransferase humain
AU688310B2 (en) Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
US7060483B1 (en) DNA encoding endo-β-galactosidase
EP2502493B1 (fr) Nouvelles alpha-galactosidases
WO1997014786A1 (fr) α-N-ACETYLGALACTOSAMINIDASE RECOMBINEE
CA2149641A1 (fr) Methodes de conversion des groupes sanguins a, ab et b en groupe o
BEAN CLONING, SEQUENCE, AND EXPRESSION OF A BLOOD GROUP B ACTIVE RECOMBINANT~-D-GALACTOSIDASE FROM PINTO BEAN
JP2004024189A (ja) 耐熱性ケラタナーゼをコードするｄｎａ
JP2001321178A (ja) 耐熱性α−ガラクトシダーゼ

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/56

A4 Supplementary search report drawn up and despatched

Effective date: 19970407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

16A New documents despatched to applicant after publication of the search report
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19970515

17Q First examination report despatched

Effective date: 19991221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031011